Boehringer Ingelheim to Commence Phase III Study Investigating the Role of BIBW 2992 as First-Line Treatment for Non-Small Cell Lung Cancer (NSCLC) Patients with EGFR Mutations

RIDGEFIELD, Conn., Aug. 3 /PRNewswire/ -- Boehringer Ingelheim announced today at the International Association for the Study of Lung Cancer's 13th World Conference on Lung Cancer (WCLC), San Francisco, CA, the initiation of a Phase III clinical study of BIBW 2992 as first-line treatment...

Unexpected role: EGFR protects cancer cells from starving

HOUSTON - A growth factor receptor found abundantly on the surface of cancer cells and long known to fuel cancer growth also protects tumor cells from starvation by a newly identified mechanism, researchers at The University of Texas M. D. Anderson Cancer Center report in the May 5 issue of Cancer...

New Antibody for EGFR Causes Lung Cancer Regression

Mutant forms of the protein EGFR are important for the development of lung cancer in a substantial proportion of individuals with this disease. However, not all individuals// express the same mutant EGFR, for example, some have a mutation that affects the intracellular part of EGFR and some have a ...

Micromet, Inc. Reports Second Quarter 2009 Financial Results

... an exclusive option to license a specified BiTE antibody against an undisclosed solid tumor target. Other BiTE antibodies targeting MSCP, CD33, HER2, egfr and other targets are in various stages of preclinical development. Forward-Looking Statements This release contains certain forward-l...

Fox Chase finds that lung cancer patients respond to erlotinib following cetuximab therapy

...ion has been that once a patient progresses on one egfr inhibitor they will not respond to another egfr inhibitor. The new data suggests that may not be t...t because a patient received and progressed on one egfr inhibitor doesn't necessarily mean they will not d...

Advanced targeted therapies effective as first-line treatment for lung cancer

...ions that cause the cells to grow and multiply. An egfr is found at abnormally high levels on the surface ...F. The drug gefitinib is intended to attach to the egfr and, thereby, inhibit the attachment of EGF and st...ine therapy and analyzed the treatment efficacy by egfr mutation status. Of 1,217 enrolled patients in IPA...

Addario Lung Cancer Medical Institute Announces Diagnostic Screening and Clinical Research Collaborations With Response Genetics, Inc.

...ncer tissues. (Logo: http://www.newscom.com/cgi-bin/prnh/20090731/DC55399LOGO ) Specific molecular features of tumors, including egfr mutations, ras mutations, ERCC1, RRM1 or TS overexpression, have been shown in multiple studies to have prognostic importance and/or be associated wit...

AstraZeneca Submits New Drug Applications for ZACTIMA(TM) in Second-Line Advanced Non-Small Cell Lung Cancer

...luding thyroid cancer. Results from the ZEPHYR (300mg monotherapy study in egfr failures in advanced NSCLC, Phase III) and ZETA (300 mg monotherapy in adva...ly advanced or metastatic (stage IIIB-IV) NSCLC after prior therapy with an egfr inhibitor. The study is running in approximately 170 centres across 23 cou...

Molecule plays early role in nonsmoking lung cancer

...ers. "Several important lung cancer drugs target egfr mutations, but these agents are ineffective in abo... cancer cell lines, the investigators learned that egfr regulates miR-21. For example, altering egfr levels caused corresponding changes in miR-21. L...

Small Molecule Might Play Big Part in Lung Cancer

...va). To test their hypothesis that miR-21 and egfr may make attractive targets for therapy, the resea...a compound called AG1478, which targets the cell's egfr and tyrosine kinase pathway. The researchers f...cer cell death when used together, suggesting that egfr plays an important role in miR-21 elevation and ca...

EGFR in Medical Technology

AVEO Presents Preclinical Efficacy Data on AV-412, a Novel Oral Tyrosine Kinase Inhibitor of EGFR/HER2 for EGFR Mutant and Drug-Resistant Lung Cancer

LOS ANGELES & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr 17, 2007 - AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of novel, targeted cancer medicines, today announced encouraging preclinical data of AV-412, a novel, next generation oral tyrosine ki...

Vectibix(R) in Combination With Chemotherapy Significantly Improved Progression-Free Survival in First-Line Metastatic Colorectal Cancer

...important role in cell growth regulation. In mCRC, egfr transmits signals through a set of intracellular p...n is always turned "on," regardless of whether the egfr has been activated or therapeutically inhibited. ...s a monotherapy for the treatment of patients with egfr expressing mCRC after disease progression on or fo...

Micromet's Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients

...ludes several novel BiTE antibodies generated with its proprietary BiTE antibody platform technology. BiTE antibodies targeting CEA, MSCP, CD33, HER2, egfr and other targets are in various stages of preclinical development. Forward-Looking Statements This release contains certain forward-looki...

Micromet Presents Update on Blinatumomab's Response Rate and Duration in a Phase 1 Study in Non-Hodgkin's Lymphoma Patients

...ludes several novel BiTE antibodies generated with its proprietary BiTE antibody platform technology. BiTE antibodies targeting CEA, MSCP, CD33, HER2, egfr and other targets are in various stages of preclinical development. Forward-Looking Statements This release contains certain forward-looki...

Video: Phase III Study Data With Vandetanib (Zactima(TM)) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented at American Society of Clinical Oncology

...ination with other anti-cancer therapies in a range of tumor types, including thyroid cancer. Results from the ZEPHYR (300mg monotherapy study in egfr failures in advanced NSCLC, Phase III) and ZETA (300 mg monotherapy in advanced medullary thyroid cancer, Phase III) studies will be available during ...

New Preliminary Data from Two Studies Show Clinical Activity of Neratinib in Combination with Trastuzumab and in Combination with Paclitaxel in Advanced HER-2 Positive Breast Cancer

... Meeting in Orlando, Florida, from May 29 to June 2, 2009. Neratinib is an investigational orally administered irreversible inhibitor of the HER-2 and egfr kinases. "The data gathered from these studies provide additional evidence suggesting that neratinib, when combined with these therapies, is an ...

Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009

... - Data on BIBW 2992, an Irreversible, Dual egfr / HER2 Tyrosine Kinase Inhibitor, Suggests Activity in Second-line Treatment of NSCLC Patients with egfr Activating Mutations - (1,2) -The First Prese... the second-line setting among NSCLC patients with egfr mutations, which is encouraging news."(2) B...

Micromet Presents Update on BiTE Antibody Pipeline and Reviews Key AACR Presentations at R&D Day

...intestinal cancer. egfr BiTE Antibody -- pre-clinical data presented at AA...tional BiTE antibodies, targeting CEA, CD33, Her2, egfr and MCSP, respectively, are in different stages of...tended utilization of blinatumomab, MT110, and its egfr BiTE antibody. You are urged to consider statement...

Micromet Presents Preclinical Data Showing Activity of Erbitux and Vectibix Based BiTE Antibodies against KRAS- and BRAF-mutated Human Colorectal Cancer Cells

...'s proprietary BiTE technology. Both of Micromet's egfr BiTE antibodies were able to direct T cells agains... destruction of these cancer cells. In mice, daily egfr BiTE antibody doses as low as 0.1 microgram/kilogr...bodies, we were able to produce novel, very potent egfr BiTE antibodies. Based on these results, we believ...

Micromet Receives Milestone Payment for Filing of the First Clinical Trial Application for MT203

... Bayer Schering Pharma AG to license a BiTE antibody against an undisclosed solid tumor target. Additional BiTE antibodies, targeting CEA, CD33, Her2, egfr and MCSP, respectively, are in different stages of preclinical development. Forward-Looking Statements This release contains certain forw...

EGFR in Biological News

Novel EGFR ectodomain mutations in glioblastoma

The Epidermal Growth Factor Receptor (EGFR), a so-called kinase protein, is often abnormally active in cancer. A new class of anticancer drugs inhibiting the activated EGFR kinase have shown to be effective against such cancers, especially lung cancer. In a new study in PLoS Medicine, researchers h...

Joining forces to improve lung cancer treatment

...al conformal radiotherapy (3D-CRT) with dose-per-fraction escalation for treatment of stage III non-small-cell lung cancer (Poland) Confirmation that egfr mutations (deletion in exon 19, missense L858R) are the most important predictors of sensitivity to tyrosine-kinase inhibitor targeted therapies (Ital...

Newly discovered epidermal growth factor receptor active in human pancreatic cancers

...ancers, Dr. Pandey realized the same receptor had been found by other researchers to be activated in a subset of lung cancers. And, most promising, an egfr inhibitor named erlotinib already has been through the long and complex Food and Drug Administration approval process and is in use for treatment of t...

Mayo researchers identify dangerous 'two-faced' protein crucial to breast cancer spread and growth

...owth mechanisms," Dr. Anastasiadis says. "A similar effect would also be expected in EGFR-positive lung cancer and anti-EGFR treatment." Both HER2 and egfr are growth-promotion proteins. A potential solution would be to design an agent that targets the tumor-promoting function of p120 that is not bound...

New technique sees into tissue at greater depth, resolution

...ies would home in on cells that were overproducing egfr on their surfaces, an indicator of cancerous activ..., we found that the cells that were overexpressing egfr gave off a signal 300 percent higher than cells wi...t cancer therapies. Tumors with elevated levels of egfr are known to have a poor prognosis, and she plans ...

How what and how much we eat (and drink) affects our risk of cancer

...tor 1 receptor (IGF-1R). We have demonstrated that dietary energy balance directly modulates activation of cell surface receptors, specifically the egfr and the IGF-1R, which subsequently affects signaling through downstream pathways, such as Akt and mTOR. Negative energy balance inhibits, while posit...

Cold Spring Harbor Laboratory's lung cancer research program awarded $100,000 grant

...s raises the possibility that interactions between egfr and estrogen might be important in the development of tumors harboring egfr mutations. Our research will build upon preliminary observations that estrogen provokes egfr activity in non-small cell lung cancer, Sordella s...

Gene variation may elevate risk of liver tumor in patients with cirrhosis

...hor. In addition, the molecular pathway controlled by EGF and its receptor egfr which is known to be important in several types of cancer appears to be a... that EGF levels were highest in the G/G patients, as was activation of the egfr receptor. In addition, blood levels of EGF were highest in those with two ...

Lung cancer cells' survival gene seen as drug target

...hosphorylated, a chemical switch that regulates processes such as cell division, growth, or death. "We knew that 14-3-3 is important in controlling egfr (epidermal growth factor receptor) signaling, which is a main pathway driving lung cancer," Dr. Fu says. A couple of recently introduced drugs that we...

$2.7 million awarded for metastatic colon cancer research

...Weiners research seeks an analytical and experimental basis for introducing new ways of treating colorectal cancers with existing agents, specifically egfr pathway-targeted drugs. He expects that these findings can act as a vast resource for future research studies of this type. Taketo of Kyoto Univ...

EGFR in Biological Technology

NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD & NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS

- Results from a randomized Phase IIb trial reported at 2009 ASCO Annual Meeting - MISSISSAUGA, ON, June 1 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: YMI , TSX:YM, AIM:YMBA), a life sciences product development company that identifies and advances a diverse portfolio ...

China Medical Technologies Completes the Development of EGFR Molecular Diagnostic Kits

BEIJING, Nov. 20 /PRNewswire-FirstCall/ -- China Medical Technologies, Inc. (the "Company") (Nasdaq: CMED ), a leading China-based medical device company that develops, manufactures and markets advanced in-vitro diagnostic products, today announced that it has successfully completed the developm...

InNexus Biotechnology Announces New EGFR Antibody DXL1218 Targeting Colorectal Cancer and Announces $1.25 Million Private Placement

- Innovative Biotech Targets Another Large Well-Known Product and Continues Expansion of Antibody Therapeutics Pipeline - BRITISH COLUMBIA, Canada, Nov. 7 /PRNewswire-FirstCall/ -- InNexus Biotechnology Inc., (OTC Bulletin Board: IXSBF; TSX Venture: IXS; http://www.ixsbio.com ), a d...

Roche Signs Exclusive Distribution Deal with DxS for K-RAS and EGFR Cancer Mutation Tests

Tests identify genetic mutations that can affect patient response to certain cancer drugs PLEASANTON, Calif., June 2 /PRNewswire/ -- Roche and DxS Ltd. have signed an exclusive distribution agreement for the DxS TheraScreen K-RAS Mutation Test and TheraScreen EGFR 29...

Micromet Closes $80.5 Million Public Offering of Common Stock

...n until January 2010 to license a specified BiTE antibody against an undisclosed solid tumor target. Other BiTE antibodies targeting MSCP, CD33, HER2, egfr and other targets are in various stages of preclinical development. Forward-Looking Statements This release contains certain forward-l...

Micromet Receives European Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia with BiTE Antibody Blinatumomab

... an exclusive option to license a specified BiTE antibody against an undisclosed solid tumor target. Other BiTE antibodies targeting MSCP, CD33, HER2, egfr and other targets are in various stages of preclinical development. Forward-Looking Statements This release contains certain forward-l...

Micromet Announces Pricing of Public Offering of Common Stock

...n until January 2010 to license a specified BiTE antibody against an undisclosed solid tumor target. Other BiTE antibodies targeting MSCP, CD33, HER2, egfr and other targets are in various stages of preclinical development. Forward-Looking Statements This release contains certain forward-l...

Micromet Announces Public Offering of Common Stock

...n until January 2010 to license a specified BiTE antibody against an undisclosed solid tumor target. Other BiTE antibodies targeting MSCP, CD33, HER2, egfr and other targets are in various stages of preclinical development. Forward-Looking Statements This release contains certain forward-l...

Micromet, Inc. to Host Conference Call and Webcast to Report Second Quarter 2009 Financial Results on August 6, 2009

... an exclusive option to license a specified BiTE antibody against an undisclosed solid tumor target. Other BiTE antibodies targeting MSCP, CD33, HER2, egfr and other targets are in various stages of preclinical development. Forward-Looking Statements This release contains certain forward-l...

Micromet Added to Russell 3000 Index

... an exclusive option to license a specified BiTE antibody against an undisclosed solid tumor target. Other BiTE antibodies targeting MSCP, CD33, HER2, egfr and other targets are in various stages of preclinical development. Forward-Looking Statements This release contains certain forward-looki...

EGFR in Biological Dictionary

AP-1

...y is inhibited in a dose ... The AP - 1 family of transcription factors consists predominantly of homodimeric ... AP - 1 activation through egfr was assessed using a β-lactamase reporter gene ... An AP - 1 response element (TGACTAA, 7X) was inserted into the MCS of the β ... To further...